Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOVENT vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular c AMP levels, and by antagonizing adenosine receptors.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of symptoms and prevention of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life 7-9 hours, prolonged in patients with hepatic impairment (up to 12 hours) or heart failure.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4. Metabolites include 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
40% bound primarily to albumin.
55–65% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg, approximating total body water.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral immediate-release: 96%; sustained-release: 80-90%.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
GFR 30-50 m L/min: reduce dose by 25%. GFR 10-29 m L/min: reduce dose by 50%. GFR <10 m L/min: reduce dose by 75% or extend interval to every 24 hours.
No dose adjustment required for renal impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: reduce dose by 75% or consider alternative therapy.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Oral: 5-10 mg/kg every 12 hours; maximum 400 mg/day. Intravenous: 5 mg/kg loading dose, then 5 mg/kg every 12 hours.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Initiate at 200 mg every 12 hours; increase cautiously to 400 mg every 12 hours; monitor renal function and adjust per renal guidelines.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No FDA black box warning.
No FDA black box warning exists for this drug.
High risk of toxicity with narrow therapeutic index; monitor serum levels,Use caution in patients with cardiac disorders (e.g., arrhythmias), liver disease, renal impairment, seizure disorders, or peptic ulcer disease,Drug interactions with fluoroquinolones, macrolides, cimetidine, allopurinol, and others can increase theophylline levels,Cigarette smoking and certain anticonvulsants can decrease theophylline levels
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or any component,Seizure disorder not adequately controlled,Active peptic ulcer disease
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid high-fat meals as they can alter absorption of sustained-release formulations. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) may increase the risk of toxicity and should be limited. Charcoal-grilled foods and a high-protein diet may reduce theophylline clearance, while a high-carbohydrate diet may increase clearance; maintain consistent diet.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
First trimester: No evidence of major malformations; second/third trimester: Risk of fetal tachycardia and intrauterine growth restriction with high maternal doses; overall pregnancy category C.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Excreted in breast milk; M/P ratio approximately 0.6; use with caution, monitor infant for irritability and tachycardia.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Increased clearance in late pregnancy may require dose increase; monitor serum levels and adjust to maintain therapeutic range (5-15 mcg/m L).
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
THEOVENT is a brand of theophylline, a methylxanthine bronchodilator. Narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with seizure disorders. Use with caution in heart failure, hepatic impairment, and elderly. Caffeine and other methylxanthines can increase toxicity. Smoking induces metabolism, requiring dose adjustments. Consider alternative in acute exacerbations due to slow onset.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it can increase side effects.,Do not smoke or stop smoking without medical advice, as smoking affects how the drug works.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Take with food if gastrointestinal upset occurs.,Do not crush or chew extended-release tablets; swallow whole.,Keep a regular dosing schedule to maintain consistent blood levels.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOVENT vs AEROLATE SR, answered by our medical review team.
THEOVENT is a Bronchodilator that works by Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular c AMP levels, and by antagonizing adenosine receptors.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOVENT and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOVENT is: Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOVENT and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOVENT is classified as Category C. First trimester: No evidence of major malformations; second/third trimester: Risk of fetal tachycardia and intrauterine growth restriction with high maternal doses; overall pregnan. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.